Table 5.
Cox regression analysis of disease-free survival and overall survival in consecutive gastric cancer patients.
| DFS | OS | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |||||
| HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | |
| Age | ||||||||
| <65 | 1.00 | - | 1.00 | 1.00 | ||||
| ≥65 | 1.31 (0.92–1.86) |
0.139 | - | - | 2.43 (1.83–3.22) |
<0.001 | 2.90 (2.18–3.87) |
<0.001 |
| Sex | ||||||||
| Male | 1.00 | - | 1.00 | 1.00 | ||||
| Female | 0.79 (0.54–1.16) |
0.230 | - | - | 0.66 (0.48–0.91) |
0.010 | 0.74 (0.53–1.01) |
0.060 |
| Lymphatic invasion | ||||||||
| Absent | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Present | 9.24 (5.46–15.62) |
<0.001 | 2.23 (1.23–4.03) |
0.008 | 30.07 (2.27–4.14) |
<0.001 | 1.40 (0.97–2.03) |
0.076 |
| Perineural invasion | ||||||||
| Absent | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Present | 7.73 (5.16–11.58) |
<0.001 | 1.45 (0.91–2.30) |
0.121 | 3.74 (2.82–4.96) |
<0.001 | 1.43 (0.99–2.08) |
0.060 |
| Vascular invasion | ||||||||
| Absent | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Present | 6.49 (4.45–9.45) |
<0.001 | 1.81 (1.23–2.66) |
0.003 | 4.95 (3.55–6.90) |
<0.001 | 2.11 (1.47–3.03) |
<0.001 |
| HER2 IHC | ||||||||
| <2+ | 1.00 | - | 1.00 | - | ||||
| ≥2+ | 0.94 (0.49–1.80) |
0.852 | - | - | 0.90 (0.54–1.51) |
0.697 | - | - |
| HER2 SISH | ||||||||
| Non-ampl | 1.00 | - | 1.00 | - | ||||
| Ampl | 0.97 (0.71–1.32) |
0.845 | - | - | 1.02 (0.61–1.70) |
0.934 | - | - |
| Trastuzumab IHC | ||||||||
| <2+ | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| ≥2+ | 2.80 (1.31–6.01) |
0.008 | 1.81 (0.84–3.90) |
0.132 | 2.19 (1.08–4.44) |
0.031 | 1.68 (0.82–3.42) |
0.155 |
| Overall HER2 status | ||||||||
| Negative | 1.00 | - | 1.00 | - | ||||
| Positive | 0.94 (0.42–2.15) |
0.891 | - | - | 0.97 (0.51–1.83) |
0.926 | - | - |
| Stage | ||||||||
| I, II | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| III, IV | 19.27 (11.66–31.85) |
<0.001 | 8.58 (4.59–16.04) |
<0.001 | 4.96 (3.73–6.60) |
<0.001 | 3.11 (2.06–4.68) |
<0.001 |
Abbreviation: PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; IHC, immunohistochemistry; SISH, silver in situ hybridization; Non-ampl., non-amplification; Ampl., amplification.